Ghafuri Djamila Labib, Chaturvedi Shruti, Rodeghier Mark, Stimpson Sarah-Jo, McClain Brandi, Byrd Jeannie, DeBaun Michael R
Academic Medical Center at the University of Amsterdam, Amsterdam, The Netherlands.
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University, Nashville, Tennessee.
Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26401. Epub 2016 Dec 30.
In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.
在一项回顾性队列研究中，我们检验了以下假设：当给镰状细胞贫血（SCA）患儿开羟基脲（HU）以预防血管闭塞性事件时，通过成像技术（TCDi）测量维持低经颅多普勒（TCD）速度会有次要益处。90.9%（120名中的110名）≥5岁的SCA患儿服用了HU，并随访了4.4年的中位数时间，70%（n = 77）在开始服用HU后接受了至少一次TCDi评估。没有服用HU的患儿有条件性或异常的TCDi测量结果。为预防疾病严重程度而开始使用HU可降低异常TCDi速度的患病率。
